Press

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Apr 21 • 4 min read

Cybin Inc. (NEO: CYBN | NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has partnered with Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company’s Phase 1/2a clinical trial of CYB003, a proprietary…

Nue Life Health, a Next-Gen Mental Wellness Platform, Announces a $23M Financing Led by Obvious Ventures and Western Technology Investment

Apr 20 • 4 min read

Nue Life Health, a breakthrough mental wellness company, today announced the completion of its Series A equity financing led by Obvious Ventures, as well as additional venture debt financing from Western Technology Investment, for a total funding of $23M. Founded in 2021, Nue Life offers an integrated therapeutic ecosystem of ketamine therapy, an interactive companion…

Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder

Apr 19 • 4 min read

Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms, is pleased to announce that following the completion of a successful Pre-IND meeting with the United States Food and Drug Administration, the Company is exploring the opportunity to expand its…

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

Apr 18 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF | CSE: RVV | FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with…

NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows

Apr 15 • 4 min read

NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced plans to launch 10 specialty mental health clinics over the next 3 years through alliances with SRx Health Solutions and BioScript Solutions, leading…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441